ABSTRACT The impact of iron-only supplements (FE) versus multiple micronutrient supplements containing iron (MM) during pregnancy on iron status was assessed in a subsample (n ϭ 453) of women who participated in a randomized double-blind trial in Mexico. Compliance, monitored by observation, was high (Ͼ85%). The two groups were similar at recruitment (Ͻ13 wk gestation) for various sociodemographic characteristics and for mean hemoglobin (Hb) concentrations and prevalence of anemia (Hb Ͻ 110 g/L; 11%). However, mean serum ferritin was higher (P Ͻ 0.05) in the MM group (n ϭ 142) compared to the FE group (n ϭ 148) and the prevalence of iron deficiency (serum ferritin Ͻ 12 g/L) was lower in the MM group (44.4%) compared to the FE group (57.4%). By the third trimester, almost half the women were anemic in both groups, and mean Hb (g/L) was lower for the MM group (104.2; 95% CI: 102.5, 106.0) compared to the FE group (108.1; 95% CI: 106.4, 109.8) after adjusting for baseline serum ferritin. In contrast, there were no differences in Hb concentrations at 1 mo postpartum or in mean ferritin and prevalence of iron deficiency at 32 wk gestation and 1 mo postpartum (90.9 and 45.1% for the MM group; 92.6 and 47.3% for the FE group, respectively). In conclusion, rather than improve Hb or iron status relative to FE-only supplements as hypothesized, MM supplements may have slightly reduced Hb concentrations during pregnancy. Neither supplement was able to meet iron needs as evidenced by dramatic increases in anemia and iron deficiency by the end of pregnancy. J. Nutr. 134: 898 -903, 2004. 
Anemia is a substantial public health problem in many developing countries and has been associated with a range of adverse consequences including poor mental development, reduced productivity, maternal mortality, and low birth weight (1) (2) (3) . Iron deficiency is considered the main cause of anemia, especially among young children and pregnant women, who are at increased risk due to their increased requirements (4) . Anemia during pregnancy, however, remains a problem in many settings despite the fact that routine provision of iron supplements has been recommended for pregnant women (5, 6) . The failure of iron supplementation programs to reduce anemia in pregnant women has been attributed to various factors that influence program delivery. These include lack of availability of supplements, poor coverage, inadequate provider knowledge, and poor compliance due to lack of motivation and/or side effects (6) . However, more recently the efficacy of iron supplements has been questioned given the complex etiology of anemia.
Anemia may result from both nutritional and nonnutritional factors. Specifically, besides iron, deficiencies of micronutrients such as vitamins A, C, and B-12 and folate may contribute to the development of anemia (4) . These nutrients may affect hemoglobin (Hb) 4 synthesis either directly or indirectly by affecting absorption and/or mobilization. For example, vitamin A has been shown to play a role in the mobilization of iron for hematopoiesis and studies have shown that vitamin A supplementation along with routine iron supplements during pregnancy substantially reduced the prevalence of anemia when compared to only iron supplements (7, 8) . Similarly, vitamin C is known to enhance iron absorption. Folate and vitamin B-12 deficiency can independently cause megaloblastic anemia that differs from microcytic irondeficiency anemia by affecting DNA synthesis.
In many developing countries, diets that are poor in iron are also poor in several other nutrients due to low intakes of animal foods and high intakes of foods rich in absorptioninhibiting factors such as phytates. This has therefore raised interest in providing nutrients besides iron to reduce the prevalence of anemia (9, 10) , but few studies have evaluated the impact of multivitamin-mineral supplements on anemia and iron status during pregnancy. Two randomized controlled trials (RCT) from Tanzania (11) and Nepal (12,13) have evaluated the benefits of multiple micronutrient supplements on pregnancy outcomes, but only one examined iron status and found that multiple micronutrients did not improve hematologic indicators when compared to patients who received iron-folate supplements (13). We recently completed an RCT that compared the effect of a daily prenatal multivitaminmineral supplement to iron-only supplements on birth outcomes (14) and examine the effects on anemia and iron status in this paper.
METHODS
Study setting and design. An RCT was carried out during 1997-2000 to compare the efficacy of a multiple micronutrient (MM) supplement compared to iron-only (FE) during pregnancy to improve birth outcomes in a semirural community near the city of Cuernavaca in Morelos, Mexico. This study was a collaborative project between the Department of International Health at Rollins School of Public Health, Emory University (Atlanta, GA) and the Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública (INSP) (Cuernavaca, Mexico). The MM supplement was designed to provide 100 -150% of the recommended dietary allowance (15) of key vitamins (700 g retinol, 2 g vitamin B-12, 66.5 mg vitamin C) and minerals (15 mg Zn) and was similar to supplements that are commercially available. The control group received only iron, the standard practice of the Ministry of Health in Mexico at the time the study was conducted. Both supplements contained 60 mg of iron in the form of ferrous sulfate. Details of supplement content, study eligibility, and recruitment are described elsewhere (14) . Informed consent was obtained from all women who agreed to participate and they were then randomly allocated to either the MM or the FE group.
Data collection. At recruitment, the study physician and a team of trained nurses conducted a prenatal examination that included a detailed obstetric history, physical examination, and anthropometric assessment at the study headquarters. The first supplement was consumed on site, following which women were visited at their homes 6 days a week until delivery by trained workers who administered and recorded the consumption of supplements. Socioeconomic status was determined using a questionnaire regarding household building materials, possessions, and occupation, from which an index of economic status was derived using factor analysis (14) . Venous blood samples were collected at the field headquarters by trained nurses from willing subjects at baseline, 32 wk of completed gestation, and 1 mo postpartum as part of routine prenatal and postpartum care. The blood samples were centrifuged at ambient temperature for 15 min at 2000 ϫ g. Serum was transferred to trace element-free microtubes, frozen immediately at Ϫ20°C, and transferred within 1 week to Ϫ70°C until analysis.
Samples were analyzed at the INSP nutrition laboratories for serum ferritin and C-reactive protein (CRP) concentrations. The quantitative measurement of ferritin in serum was determined by sandwich immunoassay (ELISA, Opus Behring Laboratories) using commercial kits (Dade Behring). CRP in serum was measured using an immunonephelometry system (16, 17) , in which polystyrene particles coated with monoclonal antibodies to CRP are agglutinated when mixed with serum samples containing CRP.
Hemoglobin concentrations were measured in the field headquarters at the same time points by trained nurses using a portable photometer (Hemocue) from a capillary blood sample obtained by finger-prick. Appropriate referral and treatment for high-risk pregnancies were provided by the study physician, who worked closely with the local health authorities. Data entry and cleaning were carried out on an ongoing basis with supervision by INSP staff at the main office in Cuernavaca. Additional data cleaning was carried out at Emory University.
Data analysis. The main outcome variables were measures of iron status and anemia at 32 wk gestation and 1 mo postpartum. Because serum ferritin was not normally distributed, log e transformed values were used. A small value of 0.0001 was added to all values to ensure appropriate transformation of "zero" values. Anemia was defined as hemoglobin concentrations below 110, 105, and 120 g/L at recruitment, 32 wk gestation and 1 mo postpartum, respectively, whereas iron deficiency was defined as serum ferritin below 12 g/L at all time points (18, 19) . Iron-deficiency anemia was indicated by the presence of both anemia and iron deficiency. Gestational age was based on recalled date of last menstrual period and overweight was defined as BMI above 25 kg/m 2 (20). Compliance was calculated by expressing the total number of tablets consumed as a percentage of the total number that they could have consumed (6 d per wk from recruitment to delivery).
The study sample for this analysis was a subsample of all pregnancies assigned to treatment between July 1997 and December 31, 1999, that resulted in singleton live births and had data on measures of iron status at recruitment, 32 wk gestation, and 1 mo postpartum. Comparisons between the final sample and those not included were done for selected baseline characteristics and measures of compliance and the comparability of the two treatment groups in the final sample was tested for selected sociodemographic, health, and nutrition characteristics of the women at recruitment. These comparisons were done using Student's t tests for means for normally distributed variables and chi-square tests of proportions for categorical variables.
Mean hemoglobin and serum ferritin concentrations were compared between supplement groups using general linear models to control for factors that differed between groups at recruitment. In the case of binary outcomes, namely anemia, iron-deficiency anemia (IDA), and iron deficiency, multivariate logistic regression models were used to compare the treatment groups. In both cases, the role of outliers and suitability of the models were examined. In addition, effect modification by characteristics selected a priori to data analysis (iron status and maternal BMI at recruitment) was tested. All statistical analyses were conducted using SAS 8.2. A P value Ͻ 0.05 for main effects and P Ͻ 0.15 for interaction terms were considered significant. Adjustments were also done for multiple comparisons as appropriate.
RESULTS
A total of 921 pregnancies were identified, of which 873 were assigned to treatment after pregnancy was confirmed, eligibility was determined, and informed consent was obtained and 645 of these pregnancies resulted in singleton live births. Loss to follow-up was about 25%, the reasons for which are explained elsewhere (14) . Hemoglobin measurements were available at baseline, 32 wk gestation, and 1 mo postpartum for a subsample of 453 of 645 women (70.2%). Serum ferritin measurements were also available at the 3 time points for a smaller sample of 290 pregnancies (Fig. 1) . Although the original design was to obtain venous blood samples only for a 30% random subsample of all pregnancies, blood samples were actually obtained from a larger number of women at the various time points and baseline data were available for hemoglobin and serum ferritin for 802 and 683 pregnancies, respectively, that were assigned to treatment. Based on sample size requirements and budgetary constraints, serum ferritin estimations were, however, done for the later time points (32 wk gestation and 1 mo postpartum) only for the first 300 samples that had baseline serum ferritin values.
The comparison of selected maternal characteristics at recruitment (Table 1) for the final sample of 453 pregnancies with complete hemoglobin data at baseline, 32 wk gestation, and 1 mo postpartum indicates that the two treatment groups were not different for the majority of characteristics including age, parity, number of weeks pregnant at entry, hemoglobin concentration, and maternal height. The groups were not different for maternal schooling, ethnicity, and economic status. However, as reported earlier, almost a third of the women were overweight, with a higher proportion (P Ͻ 0.05) in the FE group (38.8%) compared to the MM group (32.3%). The prevalence of anemia at recruitment did not differ between groups, but serum ferritin was lower in the MM group compared to the FE group in the final sample.
The comparison of the final sample (n ϭ 453) to those with incomplete blood data and/or those who were lost to follow-up (n ϭ 420) did not reveal any significant differences in baseline characteristics except that women in the final sample were less likely to be primiparous ( Table 2 ). The prevalence of anemia at baseline was also higher in the MM group (16.8%) compared to the FE group (7.3%) among those who were lost to follow-up and/or had incomplete blood data, but no differences in iron deficiency based on serum ferritin were found. Compliance and the total number of supplements consumed while in the study were lower for those lost to follow-up, as expected. Within the final sample, the subsample of 290 pregnancies with complete serum ferritin data did not reveal any differences in baseline characteristics from the rest of the sample (n ϭ 583; data not presented).
The prevalence of anemia was about 11% at recruitment and increased to 38% by 32 wk gestation and 44% at 1 mo postpartum. Compared to anemia, the prevalence of iron deficiency was much higher at recruitment and almost all women were iron deficient at 32 wk gestation, and about half remained deficient at 1 mo postpartum. The prevalence of IDA during pregnancy suggests that most of the anemia was due to iron deficiency. About two-thirds of anemia was due to iron deficiency at 1 mo postpartum. Comparisons of the prevalence of anemia, iron deficiency, and IDA by treatment group (Table 3) reveal no differences at 32 wk gestation and 1 mo postpartum. Although the prevalence of anemia was similar at both time points (P Ͼ 0.05), iron deficiency was higher (P ϭ 0.026) at baseline in the iron group and controlling for these differences indicated a higher risk of anemia (P ϭ 0.014) and IDA (P ϭ 0.026) in the MM group compared to the FE group at 32 wk gestation. The adjusted odds ratios (AOR) were 2.05 (95% CI: 1.16, 3.62) and 1.88 (95% CI: 1.08, 3.28) for anemia and IDA, respectively. Further adjustment for baseline differences in BMI attenuated these findings (P Ͼ 0.025). There were no differences in any of the outcomes at 1 mo postpartum after adjustment for baseline iron status and BMI, nor did either modify the effect of supplementation on any outcomes.
Comparison of mean hemoglobin concentrations at 32 wk gestation and 1 mo postpartum by treatment group (Table 4) revealed that although mean hemoglobin concentrations were similar in both groups before adjusting for baseline serum ferritin, mean Hb concentrations were significantly higher in the FE group compared to the MM group at 32 wk gestation following adjustment for baseline serum ferritin. Comparison of mean serum ferritin (log transformed) concentrations at 32 wk gestation and 1 mo postpartum revealed no significant differences by treatment group before and after adjusting for baseline serum ferritin. 
FIGURE 1
Flow chart for study samples with hemoglobin and serum ferritin measurements at baseline, 32 wk gestation, and 1 mo postpartum. 1 A total of 361 also have baseline serum ferritin. 2 Final sample with Hb and serum ferritin measures at baseline, 32 wk gestation, and 1 mo postpartum.
DISCUSSION
Our results clearly indicate that multiple micronutrient supplements during pregnancy were not more efficacious in reducing anemia or iron deficiency compared to iron-only supplements. The prevalence of anemia and iron deficiency was similar in both groups at 1 mo postpartum and these null findings cannot be attributed to low compliance or lack of statistical power. Poststudy calculations revealed that, using a two-tailed test with a significance level of 0.05, our sample sizes of 453 and 290 had Ͼ80% power to detect a difference of at least 4 g/L (0.28 SD) and 0.35 log g/L (0.35 SD) in mean hemoglobin and serum ferritin concentrations, respectively, which represent small to medium effect sizes. In fact, although mean hemoglobin concentrations at 32 wk gestation were similar in both groups, the differences were significant in favor of the iron group following adjustment for the baseline serum ferritin that differed by intervention group. Similarly, although the unadjusted prevalence of anemia was not significantly different between treatment groups at 32 wk gestation, the risk of anemia nearly doubled for the MM group compared to the FE group following adjustment for baseline serum ferritin. Although the differences in hemoglobin cannot be explained by differences in iron status, the significance of these findings is unclear. It should also be noted that adjustment for baseline serum ferritin may not have been required, because the difference in serum ferritin between treatment groups was not seen in the larger sample of pregnancies that had baseline values of serum ferritin (n ϭ 683). The potential for selection bias as a result of a higher prevalence of anemia at baseline in the MM group (16.8%) compared to the FE group (7.3%) among those lost to follow-up and/or those who had incomplete blood data is also a concern, although there were no differences in iron deficiency based on serum ferritin.
The lack of benefit of MM supplements to improve iron status during pregnancy may be due to several reasons. Vitamin A may not have benefited our study population because the prevalence of deficiency was much lower when compared to the study in Indonesia that demonstrated reductions in anemia by vitamin A supplementation (7, 21) . Similarly, the contribution of folate and vitamin B-12 deficiencies to anemia may also have been less than expected as suggested by the similar prevalence of IDA and overall anemia at recruitment. Another important issue is the potential adverse interaction between iron and zinc (22, 23) . Zinc may have reduced the bioavailability of iron and therefore overridden any benefits that may have been attributable to other enhancers of iron absorption such as vitamin C. Although little is known about the bioavailability of nutrients in multiple micronutrient supplements, results from an intervention trial in Peru showed that although iron interfered with zinc bioavailability (24) , the inclusion of 15 mg zinc along with 60 mg iron and folate did not adversely affect changes in hemoglobin and iron status during pregnancy when compared to just iron-folate (25, 26) . Our supplements contained similar amounts of these nutrients and it therefore seems unlikely that competition between iron and zinc in the supplement explains the lack of impact.
Although the prevalence of anemia at recruitment was much lower than that reported in other developing countries, almost half the women had iron deficiency and these rates increased dramatically during pregnancy despite iron supplementation. The high prevalence of iron deficiency at 32 wk gestation and even at 1 mo postpartum was indeed surprising and cannot be attributed to low rates of compliance. It is not clear whether our serum ferritin values were affected by other factors, but controlling for levels of serum CRP, a marker for infections, did not alter our conclusions (results not shown). These findings suggest that iron supplementation during pregnancy is not adequate to compensate the high demands, especially in the context of poor prepregnant iron status, and emphasize the need for strategies to improve prepregnant nutritional status. Of particular interest are recent findings from an RCT in Tanzania (27) indicating that compared to a placebo, daily consumption of a multiple micronutrient-fortified beverage during pregnancy was effective in reducing anemia and preventing iron deficiency, especially among those who had IDA at baseline. Although it is not clear whether this intervention was more effective than iron supplements, the prevalence of iron deficiency at follow-up (8 wk) was much lower in the intervention group compared to both of our study groups and this approach may be more sustainable and could be used to improve micronutrient status of all women of reproductive age.
In conclusion, our study indicates that multivitaminmineral supplements during pregnancy do not improve hematologic and iron status compared to iron only. These findings are consistent with recent data from Nepal where no additional benefits were seen in hematologic status during pregnancy by multiple micronutrient supplements compared to iron-folate supplements (13). Furthermore, both the above study and our work in Mexico (12,14) failed to detect any benefits of MM supplements for birth outcomes although an earlier trial conducted in HIVϩ women in Tanzania demonstrated reductions in the prevalence of low birth weight and prematurity (11). Without doubt, we must proceed with caution, especially since we do not have any compelling evidence to date to provide multivitamin-mineral supplements in lieu of iron supplements. 
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